Marco Metra to Betacoronavirus
This is a "connection" page, showing publications Marco Metra has written about Betacoronavirus.
Connection Strength
0.279
-
Implications for the Care of Patients With COVID-19 and Inflammatory Myocardial Disease-Reply. JAMA Cardiol. 2020 11 01; 5(11):1306-1307.
Score: 0.039
-
Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020 Jun; 22(6):941-956.
Score: 0.038
-
Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 07 01; 5(7):819-824.
Score: 0.038
-
COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. Eur J Heart Fail. 2020 Jun; 22(6):957-966.
Score: 0.038
-
June 2020 at a glance: focus on COVID-19, quality of life and comorbidities. Eur J Heart Fail. 2020 06; 22(6):917-918.
Score: 0.038
-
Impact of COVID-2019 outbreak on prevalence, clinical presentation and outcomes of ST-elevation myocardial infarction. J Cardiovasc Med (Hagerstown). 2020 Nov; 21(11):874-881.
Score: 0.010
-
Coronavirus disease 2019 (COVID-19) in the heart transplant population: a single-centre experience. Eur J Cardiothorac Surg. 2020 11 01; 58(5):899-906.
Score: 0.010
-
ACE2 down-regulation may contribute to the increased thrombotic risk in COVID-19. Eur Heart J. 2020 09 01; 41(33):3200.
Score: 0.010
-
Atrial fibrillation in the COVID-19 era: simple bystander or marker of increased risk? Eur Heart J. 2020 07 01; 41(32):3094.
Score: 0.009
-
Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2020 06 07; 41(22):2109-2117.
Score: 0.009
-
Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur Heart J. 2020 05 14; 41(19):1821-1829.
Score: 0.009
-
Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. Ann Rheum Dis. 2020 06; 79(6):724-726.
Score: 0.009
-
COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs Turk J Med Sci. 2020 04 21; 50(SI-1):620-632.
Score: 0.009
-
Coronavirus disease 2019 and cardiovascular implications. J Cardiovasc Med (Hagerstown). 2020 10; 21(10):725-732.
Score: 0.002
-
The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress. Clin Rheumatol. 2020 Jul; 39(7):2043-2047.
Score: 0.002
-
Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. Eur Heart J. 2020 05 14; 41(19):1810-1817.
Score: 0.002
-
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020 Jul; 19(7):102568.
Score: 0.002
-
ST-Elevation Myocardial Infarction in Patients With COVID-19: Clinical and Angiographic Outcomes. Circulation. 2020 06 23; 141(25):2113-2116.
Score: 0.002
-
Centralization of the ST elevation myocardial infarction care network in the Lombardy region during the COVID-19 outbreak. Int J Cardiol. 2020 08 01; 312:24-26.
Score: 0.002